tiprankstipranks

Regeneron price target lowered to $1,081 from $1,150 at Morgan Stanley

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue